ID   SK-MEL-131
AC   CVCL_6081
SY   SK-Mel-131; SK-mel-131; SK-Mel 131; SK Mel 131; Sk Mel131; SKMEL-131; FD-Mel
DR   cancercelllines; CVCL_6081
DR   Cosmic; 851055
DR   Cosmic; 706112
DR   Cosmic; 721849
DR   Cosmic; 888847
DR   Cosmic; 923394
DR   Cosmic; 933132
DR   Cosmic; 1020273
DR   Cosmic; 1060428
DR   Cosmic; 1507595
DR   Cosmic; 1669171
DR   Cosmic; 2233672
DR   Wikidata; Q54953816
RX   PubMed=2453881;
RX   PubMed=2983346;
RX   PubMed=6864164;
RX   PubMed=7175440;
RX   PubMed=7509835;
RX   PubMed=7747814;
RX   PubMed=9598804;
RX   PubMed=9692547;
RX   PubMed=10766161;
RX   PubMed=15009714;
RX   PubMed=21725359;
RX   PubMed=24576830;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Heterozygous (PubMed=9598804).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15009714; PubMed=21725359; PubMed=24576830).
DI   NCIt; C4633; Amelanotic cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 25
//
RX   PubMed=2453881; DOI=10.1073/pnas.85.11.3965;
RA   Real F.X., Furukawa K.S., Mattes M.J., Gusik S.A., Cordon-Cardo C.,
RA   Oettgen H.F., Old L.J., Lloyd K.O.;
RT   "Class 1 (unique) tumor antigens of human melanoma: identification of
RT   unique and common epitopes on a 90-kDa glycoprotein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:3965-3969(1988).
//
RX   PubMed=2983346; DOI=10.1073/pnas.82.5.1470;
RA   Dracopoli N.C., Houghton A.N., Old L.J.;
RT   "Loss of polymorphic restriction fragments in malignant melanoma:
RT   implications for tumor heterogeneity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985).
//
RX   PubMed=6864164; DOI=10.1084/jem.158.1.53;
RA   Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F.,
RA   Old L.J.;
RT   "Detection of cell surface and intracellular antigens by human
RT   monoclonal antibodies. Hybrid cell lines derived from lymphocytes of
RT   patients with malignant melanoma.";
RL   J. Exp. Med. 158:53-65(1983).
//
RX   PubMed=7175440; DOI=10.1084/jem.156.6.1755;
RA   Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J.;
RT   "Surface antigens of melanocytes and melanomas. Markers of melanocyte
RT   differentiation and melanoma subsets.";
RL   J. Exp. Med. 156:1755-1766(1982).
//
RX   PubMed=7509835; DOI=10.1111/1523-1747.ep12371784;
RA   Bouchard B., Vijayasaradhi S., Houghton A.N.;
RT   "Production and characterization of antibodies against human
RT   tyrosinase.";
RL   J. Invest. Dermatol. 102:291-295(1994).
//
RX   PubMed=7747814;
RA   Gruis N.A., Weaver-Feldhaus J.M., Liu Q.-Y., Frye C., Eeles R., Orlow I.,
RA   Lacombe L., Ponce-Castaneda V., Lianes P., Latres E., Skolnick M.H.,
RA   Cordon-Cardo C., Kamb A.;
RT   "Genetic evidence in melanoma and bladder cancers that p16 and p53
RT   function in separate pathways of tumor suppression.";
RL   Am. J. Pathol. 146:1199-1206(1995).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//
RX   PubMed=9692547; DOI=10.1038/sj.onc.1201881;
RA   Tsao H., Zhang X., Benoit E., Haluska F.G.;
RT   "Identification of PTEN/MMAC1 alterations in uncultured melanomas and
RT   melanoma cell lines.";
RL   Oncogene 16:3397-3402(1998).
//
RX   PubMed=10766161;
RA   Tsao H., Zhang X., Fowlkes K., Haluska F.G.;
RT   "Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous
RT   melanoma cell lines.";
RL   Cancer Res. 60:1800-1804(2000).
//
RX   PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x;
RA   Tsao H., Goel V., Wu H., Yang G., Haluska F.G.;
RT   "Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1
RT   inactivation in melanoma.";
RL   J. Invest. Dermatol. 122:337-341(2004).
//
RX   PubMed=21725359; DOI=10.1038/onc.2011.250;
RA   Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M.,
RA   She Q.-B., Gallardo H., Liu C., Merghoub T., Hefter B., Dolgalev I.,
RA   Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G.,
RA   Wolchok J.D., Houghton A.N., Solit D.B.;
RT   "Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF
RT   dependence in melanomas harboring (V600E)BRAF.";
RL   Oncogene 31:446-457(2012).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625;
RA   Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L.,
RA   Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A.,
RA   Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F.,
RA   Rosen N., Solit D.B.;
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//